

Diagnosis and Treatment of Overactive Bladder (Non-N Guideline

Journal of Urology

188, 2455-2463

DOI: [10.1016/j.juro.2012.09.079](https://doi.org/10.1016/j.juro.2012.09.079)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Intravesical treatments of bladder pain syndrome/interstitial cystitis. <i>Nature Reviews Urology</i> , 2012, 9, 707-720.	1.9	49
2	Percutaneous Tibial Nerve Stimulation: A Clinically and Cost Effective Addition to the Overactive Bladder Algorithm of Care. <i>Current Urology Reports</i> , 2012, 13, 327-334.	1.0	71
3	Update on Behavioral and Physical Therapies for Incontinence and Overactive Bladder: The Role of Pelvic Floor Muscle Training. <i>Current Urology Reports</i> , 2013, 14, 457-464.	1.0	66
4	Urodynamics: Examining the Current Role of UDS Testing. What is the Role of Urodynamic Testing in Light of Recent AUA Urodynamics and Overactive Bladder Guidelines and the VALUE Study?. <i>Current Urology Reports</i> , 2013, 14, 403-408.	1.0	23
5	β3-Receptor Agonists for Overactive Bladder—New Frontier or More of the Same?. <i>Current Urology Reports</i> , 2013, 14, 435-441.	1.0	11
6	Neuromodulation for overactive bladder. <i>Nature Reviews Urology</i> , 2013, 10, 513-521.	1.9	64
7	Sacral Neuromodulation in Patients with Idiopathic Overactive Bladder after Initial Botulinum Toxin Therapy. <i>Journal of Urology</i> , 2013, 190, 2148-2152.	0.2	35
8	Electrical and Mechanical Office-based Neuromodulation. <i>Urologic Clinics of North America</i> , 2013, 40, 581-589.	0.8	7
9	Office-Based Behavioral Therapy for Management of Incontinence and Other Pelvic Disorders. <i>Urologic Clinics of North America</i> , 2013, 40, 613-635.	0.8	41
10	Functional Outcomes of Augmentation Cystoplasty in the non-Neurogenic Patient. <i>Current Bladder Dysfunction Reports</i> , 2013, 8, 336-343.	0.2	1
11	Tolterodine for the treatment of urge urinary incontinence. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1987-1991.	0.9	7
12	Validation of the Spanish Version of the Questionnaire «Benefit, Satisfaction and Willingness to Continue the Treatment» in patients with overactive bladder. <i>Actas Urológicas Españolas (English)</i> Tj ETQq1 1 @.784314 pgBT /Over		
13	Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline. <i>Yearbook of Urology</i> , 2013, 2013, 47-48.	0.1	15
14	Validación de la versión española del cuestionario «Beneficio, satisfacción y disposición para continuar el tratamiento» en pacientes con vejiga hiperactiva. <i>Actas Urológicas Españolas</i> , 2013, 37, 473-479.	0.3	4
15	Protective Effect of a β3-Adrenoceptor Agonist on Bladder Function in a Rat Model of Chronic Bladder Ischemia. <i>European Urology</i> , 2013, 64, 664-671.	0.9	49
16	Long-Term Patterns of Use and Treatment Failure With Anticholinergic Agents for Overactive Bladder. <i>Clinical Therapeutics</i> , 2013, 35, 1744-1751.	1.1	100
17	Re: Characteristics of Persons with Overactive Bladder of Presumed Neurologic Origin: Results from the Boston Area Community Health (BACH) Survey. <i>Journal of Urology</i> , 2013, 190, 977-977.	0.2	0
18	Risk Factors for the Failure of Antimuscarinic Treatment With Solifenacin in Women With Overactive Bladder. <i>Urology</i> , 2013, 82, 1044-1048.	0.5	6

#	ARTICLE	IF	CITATIONS
19	Long-term safety, efficacy, and tolerability of imidafenacin in the treatment of overactive bladder: a review of the Japanese literature. <i>Patient Preference and Adherence</i> , 2013, 7, 111.	0.8	14
20	The management of overactive bladder syndrome: a review of the European Association of Urology Guidelines. <i>Clinical Practice (London, England)</i> , 2013, 10, 593-606.	0.1	3
21	New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA. <i>Therapeutics and Clinical Risk Management</i> , 2013, 9, 161.	0.9	44
22	Are urodynamics still useful?. <i>Canadian Urological Association Journal</i> , 2013, 7, 452.	0.3	0
23	Short-term Effects of a Systematized Bladder Training Program for Idiopathic Overactive Bladder: A Prospective Study. <i>International Neurourology Journal</i> , 2013, 17, 11.	0.5	26
24	Increased Serum Adipokines Implicate Chronic Inflammation in the Pathogenesis of Overactive Bladder Syndrome Refractory to Antimuscarinic Therapy. <i>PLoS ONE</i> , 2013, 8, e76706.	1.1	27
25	Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection on Elderly Patients with Chronic Central Nervous System Lesions and Overactive Bladder. <i>PLoS ONE</i> , 2014, 9, e105989.	1.1	30
26	Overactive bladder in the vulnerable elderly. <i>Research and Reports in Urology</i> , 2014, 6, 131.	0.6	26
27	OnabotulinumtoxinA for the treatment of overactive bladder. <i>Research and Reports in Urology</i> , 2014, 6, 79.	0.6	20
28	Double anticholinergic therapy for refractory neurogenic and non-neurogenic detrusor overactivity in children: Long-term results of a prospective open-label study. <i>Canadian Urological Association Journal</i> , 2014, 8, 175.	0.3	18
29	Defining response and non-response to treatment in patients with overactive bladder: a systematic review. <i>Current Medical Research and Opinion</i> , 2014, 30, 509-526.	0.9	19
30	Management of Overactive Bladder Refractory to Medical Therapy. <i>Current Bladder Dysfunction Reports</i> , 2014, 9, 336-340.	0.2	1
31	Mixed Incontinence: What Takes Precedence in Its Management?. <i>Current Urology Reports</i> , 2014, 15, 461.	1.0	10
32	Tolterodine extended release in the treatment of male oab/storage luts: a systematic review. <i>BMC Urology</i> , 2014, 14, 84.	0.6	13
33	Advances in female urology and voiding dysfunction. <i>Nature Reviews Urology</i> , 2014, 11, 613-614.	1.9	0
34	Protocol for a prospective neuroimaging study investigating the supraspinal control of lower urinary tract function in healthy controls and patients with non-neurogenic lower urinary tract symptoms. <i>BMJ Open</i> , 2014, 4, e004357.	0.8	5
35	Overactive Bladder: OTC Oxybutynin Transdermal Patch for Women. <i>The Consultant Pharmacist</i> , 2014, 29, 703-707.	0.4	2
36	Best practice in the use of onabotulinumtoxinA (BOTOX®) to optimize patient outcomes in overactive bladder. <i>Neurourology and Urodynamics</i> , 2014, 33, S1.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Urinary incontinence in women. <i>BMJ</i> , The, 2014, 349, g4531-g4531.	3.0	156
38	Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO). <i>Neurourology and Urodynamics</i> , 2014, 33, S21-5.	0.8	54
39	Chapter 6: Practical aspects of administration of onabotulinumtoxinA. <i>Neurourology and Urodynamics</i> , 2014, 33, S32-7.	0.8	27
40	Predictors of short-term overactive bladder symptom improvement after transurethral resection of prostate in men with benign prostatic obstruction. <i>International Journal of Urology</i> , 2014, 21, 1035-1040.	0.5	29
42	Safety and tolerability of the β_3 adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial. <i>International Journal of Clinical Practice</i> , 2014, 68, 972-985.	0.8	70
43	Impact of urinary incontinence on healthcare resource utilization, health-related quality of life and productivity in patients with overactive bladder. <i>BJU International</i> , 2014, 113, 484-491.	1.3	83
44	Clinical safety, tolerability and efficacy of combination tolterodine/pilocarpine in patients with overactive bladder. <i>International Journal of Clinical Practice</i> , 2014, 68, 986-994.	0.8	18
45	An observational study of patient satisfaction with fesoterodine in the treatment of overactive bladder: effects of additional educational material. <i>International Journal of Clinical Practice</i> , 2014, 68, 1074-1080.	0.8	7
46	Female Mixed Urinary Incontinence. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2007.	3.8	44
47	The role of electrical stimulation techniques in the management of the male patient with urgency incontinence. <i>Current Opinion in Urology</i> , 2014, 24, 560-565.	0.9	2
48	OAB symptoms. <i>Current Opinion in Urology</i> , 2014, 24, 345-351.	0.9	5
49	Application of guidelines to the evaluation of the male patient with urgency and/or incontinence. <i>Current Opinion in Urology</i> , 2014, 24, 547-552.	0.9	2
50	Long-term use of solifenacin in pediatric patients with overactive bladder: Extension of a prospective open-label study. <i>Canadian Urological Association Journal</i> , 2014, 8, 118.	0.3	33
51	Re: The Effect of Systematic Screening of Older Women for Urinary Incontinence on Treatment Uptake: The URINO Trial. <i>Journal of Urology</i> , 2014, 191, 1343-1343.	0.2	0
52	What's in a Name?. <i>Journal of Urology</i> , 2014, 191, 7-8.	0.2	2
53	Cystectomy With Urinary Diversion for Benign Disease: Indications and Outcomes. <i>Urology</i> , 2014, 83, 1433-1437.	0.5	41
54	Pilot Study of Liposome-encapsulated OnabotulinumtoxinA for Patients with Overactive Bladder: A Single-center Study. <i>European Urology</i> , 2014, 65, 1117-1124.	0.9	100
55	Do Patient Characteristics Predict Responsiveness to Treatment of Overactive Bladder With Antimuscarinic Agents?. <i>Urology</i> , 2014, 83, 1023-1029.	0.5	17

#	ARTICLE	IF	CITATIONS
56	Role of Topical Vaginal Estrogen in the Treatment of Overactive Bladder. <i>Current Bladder Dysfunction Reports</i> , 2014, 9, 58-62.	0.2	1
57	Neuromodulation for Voiding Dysfunction: When and How Best to Use. <i>Current Bladder Dysfunction Reports</i> , 2014, 9, 41-47.	0.2	1
58	Cost effectiveness of radiofrequency microremodeling for stress urinary incontinence. <i>International Urogynecology Journal</i> , 2014, 25, 517-523.	0.7	9
59	Pelvic Floor Muscle Training in Males: Practical Applications. <i>Urology</i> , 2014, 84, 1-7.	0.5	50
60	The effect of oral solifenacin succinate treatment on intraocular pressure: glaucoma paradox during overactive bladder treatment. <i>International Urogynecology Journal</i> , 2014, 25, 1479-1482.	0.7	9
61	Melioidosis: refining management of a tropical time bomb. <i>Lancet, The</i> , 2014, 383, 762-764.	6.3	15
62	Bladder Instillation of Liposome Encapsulated OnabotulinumtoxinA Improves Overactive Bladder Symptoms: A Prospective, Multicenter, Double-Blind, Randomized Trial. <i>Journal of Urology</i> , 2014, 192, 1743-1749.	0.2	88
63	Treatment Options for Post-Prostatectomy Incontinence. <i>Urology Practice</i> , 2014, 1, 194-197.	0.2	1
64	Sacral Neuromodulation in Patients with Idiopathic Overactive Bladder after Initial Botulinum Toxin Therapy. <i>Yearbook of Urology</i> , 2014, 2014, 63-64.	0.1	0
65	Chiropractic Management of Pubic Symphysis Shear Dysfunction in a Patient With Overactive Bladder. <i>Journal of Chiropractic Medicine</i> , 2014, 13, 81-89.	0.3	3
66	Phase II drugs that target cholinergic receptors for the treatment of overactive bladder. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1365-1374.	1.9	10
67	Urodynamics in the Evaluation of Female LUTS. <i>Urologic Clinics of North America</i> , 2014, 41, 429-438.	0.8	13
68	A retrospective comparison of ring pessary and multicomponent behavioral therapy in managing overactive bladder. <i>International Urogynecology Journal</i> , 2014, 25, 1583-1588.	0.7	6
69	Efficacy and tolerability of solifenacin in men with overactive bladder: results of an observational study. <i>World Journal of Urology</i> , 2014, 32, 1041-1047.	1.2	13
70	Urgency After a Slings: Review of the Management. <i>Current Urology Reports</i> , 2014, 15, 400.	1.0	31
71	The patient perspective on overactive bladder: a mixed-methods needs assessment. <i>BMC Family Practice</i> , 2014, 15, 96.	2.9	24
72	Management of Refractory OAB in the Non-Neurogenic Patient. <i>Current Urology Reports</i> , 2014, 15, 438.	1.0	10
73	Pelvic floor muscle training for pelvic organ prolapse. <i>Lancet, The</i> , 2014, 383, 760-762.	6.3	6

#	ARTICLE	IF	CITATIONS
75	Optimum Management of Overactive Bladder: Medication vs Botox vs InterStim vs Urgent PC. <i>Urology Practice</i> , 2014, 1, 7-12.	0.2	6
76	Re: Risk Factors for the Failure of Antimuscarinic Treatment with Solifenacin in Women with Overactive Bladder. <i>Journal of Urology</i> , 2014, 191, 1822-1825.	0.2	0
77	Electrical Stimulation of Somatic Afferent Nerves in the Foot Increases Bladder Capacity in Healthy Human Subjects. <i>Journal of Urology</i> , 2014, 191, 1009-1013.	0.2	17
78	The Overlap and Distinction of Self-Reported Symptoms between Interstitial Cystitis/Bladder Pain Syndrome and Overactive Bladder: A Questionnaire Based Analysis. <i>Journal of Urology</i> , 2014, 192, 1679-1686.	0.2	35
79	Treatment of Refractory Nonneurogenic (Idiopathic) Overactive Bladder. <i>Postgraduate Obstetrics & Gynecology</i> , 2014, 34, 1-5.	0.1	0
80	Treatment of Refractory Nonneurogenic (Idiopathic) Overactive Bladder. <i>Postgraduate Obstetrics & Gynecology</i> , 2014, 34, 6.	0.1	0
81	Beta-3 adrenergic receptor agonist for adult with overactive bladder. <i>The Cochrane Library</i> , 0, , .	1.5	1
82	Botulinum toxin (OnabotulinumtoxinA) in the male non-neurogenic overactive bladder: clinical and quality of life outcomes. <i>BJU International</i> , 2015, 116, 61-65.	1.3	27
83	Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6 months in subjects with mild symptoms of overactive bladder. <i>Neurourology and Urodynamics</i> , 2015, 34, 224-230.	0.8	160
84	Prevalence, management and outcomes of medically complex vulnerable elderly patients with urinary incontinence in the United States. <i>International Journal of Clinical Practice</i> , 2015, 69, 1517-1524.	0.8	22
85	Investigating Detrusor Muscle Concentrations of Oxybutynin After Intravesical Delivery in an Ex Vivo Porcine Model. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 2233-2240.	1.6	5
89	Advances in the Treatment of Urinary Incontinence in Women. <i>Clinical Medicine Insights Urology</i> , 2015, 8, CMU.S13181.	0.4	1
90	Interventions do not enhance medication persistence and compliance in patients with overactive bladder: a 24-weeks, randomised, open-label, multi-center trial. <i>International Journal of Clinical Practice</i> , 2015, 69, 1309-1315.	0.8	8
91	Does Increasing or Decreasing the Daily Intake of Water/Fluid by Adults Affect Overactive Bladder Symptoms?. <i>Journal of Wound, Ostomy and Continence Nursing</i> , 2015, 42, 614-620.	0.6	11
92	New evidence in the treatment of overactive bladder. <i>Current Opinion in Obstetrics and Gynecology</i> , 2015, 27, 366-372.	0.9	8
93	Pelvic Floor Physical Therapy as Primary Treatment of Pelvic Floor Disorders With Urinary Urgency and Frequency-Predominant Symptoms. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2015, 21, 252-256.	0.6	17
94	Using the Jigsaw Technique to Teach Clinical Controversy in a Clinical Skills Course. <i>American Journal of Pharmaceutical Education</i> , 2015, 79, 90.	0.7	26
95	Comparison of Short Term Outcomes of Sacral Nerve Stimulation and Intradetrusor Injection of OnabotulinumtoxinA (Botox) in Women With Refractory Overactive Bladder. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2015, 21, 369-373.	0.6	17

#	ARTICLE	IF	CITATIONS
97	Overactive bladder. F1000Research, 2015, 4, 1406.	0.8	12
98	A survey on the management of overactive bladder by Indonesian urologists. Medical Journal of Indonesia, 2015, 24, 91-6.	0.2	1
99	Degradation of Microcellular PLGA-PEG Copolymer for Use in a Drug Delivery System for the Urinary Bladder. Plastics Engineering, 2015, 71, 60-64.	0.1	4
100	Future directions in overactive bladder treatment: Personalized medicine can be applied?. Korean Journal of Urology, 2015, 56, 671.	1.2	2
101	Practical Aspects of Botulinum Toxin-A Treatment in Patients With Overactive Bladder Syndrome. International Neurourology Journal, 2015, 19, 213-219.	0.5	16
102	Prediction of Nocturia Severity in Men. JAMA Surgery, 2015, 150, 125.	2.2	9
103	Female Pelvic Surgery. , 2015, , .		1
104	SIU Newsletter - June 2015. World Journal of Urology, 2015, 33, 893-904.	1.2	1
105	Solabegron: a potential future addition to the β -3 adrenoceptor agonist armamentarium for the management of overactive bladder. Expert Opinion on Investigational Drugs, 2015, 24, 413-419.	1.9	5
106	A current perspective on geriatric lower urinary tract dysfunction. Korean Journal of Urology, 2015, 56, 266.	1.2	35
107	Comparison of OnabotulinumtoxinA Intradetrusor Injection Needle Performance with Modern Flexible Cystoscopes. Journal of Endourology, 2015, 29, 1309-1313.	1.1	0
108	Comparative Effectiveness of Anticholinergic Therapy for Overactive Bladder in Women. Obstetrics and Gynecology, 2015, 125, 1423-1432.	1.2	60
109	The Worldwide Economic Impact of Neurogenic Bladder. Current Bladder Dysfunction Reports, 2015, 10, 350-354.	0.2	10
110	El valor de la oxibutinina en parche transdérmico en el tratamiento de la vejiga hiperactiva. Actas Urológicas Españolas, 2015, 39, 599-604.	0.3	8
111	The value of oxybutynin in transdermal patches for treating overactive bladder. Actas Urológicas Españolas (English Edition), 2015, 39, 599-604.	0.2	5
112	Outcomes of Sacral Neuromodulation for Overactive Bladder in Octogenarian Females. Urology Practice, 2015, 2, 22-25.	0.2	2
113	Development of an Integrated Mobile Application for Evaluating Voiding Dysfunction: A Proof of Concept Study. Urology Practice, 2015, 2, 7-11.	0.2	1
114	An update on the pharmacotherapy for lower urinary tract dysfunction. Expert Opinion on Pharmacotherapy, 2015, 16, 79-93.	0.9	19

#	ARTICLE	IF	CITATIONS
115	Acupuncture for adults with overactive bladder: a systematic review protocol. <i>BMJ Open</i> , 2015, 5, e006756-e006756.	0.8	6
116	Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom. <i>Clinical Drug Investigation</i> , 2015, 35, 83-93.	1.1	22
117	Percutaneous Tibial Nerve Stimulation and Sacral Neuromodulation: an Update. <i>Current Urology Reports</i> , 2015, 16, 4.	1.0	64
118	Differentiation and interaction of tibial versus spinal nerve stimulation for micturition control in the rat. <i>Neurourology and Urodynamics</i> , 2015, 34, 92-97.	0.8	12
120	Mixed Urinary Incontinence: What First?. <i>Current Urology Reports</i> , 2015, 16, 9.	1.0	17
121	Diet Modification for Overactive Bladder: an Evidence-Based Review. <i>Current Bladder Dysfunction Reports</i> , 2015, 10, 25-30.	0.2	4
122	New Treatments for Incontinence. <i>Advances in Chronic Kidney Disease</i> , 2015, 22, 279-288.	0.6	10
123	Highlights of the University of Toronto Urology Update 2014. <i>Canadian Urological Association Journal</i> , 2015, 9, 3.	0.3	0
124	Tolterodine in the Treatment of Male LUTS. <i>Current Urology Reports</i> , 2015, 16, 60.	1.0	9
125	Efficacy and duration of response to botulinum neurotoxin A (onabotulinumA) as a treatment for detrusor overactivity in women. <i>International Urogynecology Journal</i> , 2015, 26, 1605-1612.	0.7	21
127	Perspectives on mirabegron in the treatment of overactive bladder syndrome: A new beta-3 adrenoceptor agonist. <i>Urological Science</i> , 2015, 26, 17-23.	0.2	10
129	Refractory overactive bladder: a common problem?. <i>International Urogynecology Journal</i> , 2015, 26, 1407-1414.	0.7	13
130	Evaluation and Treatment of Overactive Bladder after History of Cancer Treatment. <i>Current Bladder Dysfunction Reports</i> , 2015, 10, 31-38.	0.2	0
131	Challenges in the Treatment of Overactive Bladder in the Octogenarian Female. <i>Current Bladder Dysfunction Reports</i> , 2015, 10, 14-19.	0.2	0
132	Correlation between psychological stress levels and the severity of overactive bladder symptoms. <i>BMC Urology</i> , 2015, 15, 14.	0.6	81
133	Economic evaluation of pharmacological treatments for overactive bladder from the perspective of the UK National Health Service. <i>Journal of Medical Economics</i> , 2015, 18, 390-397.	1.0	8
135	Improving Outcomes in Patients With Refractory Idiopathic and Neurogenic Detrusor Overactivity: Management Strategies. <i>Archives of Physical Medicine and Rehabilitation</i> , 2015, 96, S341-S357.e1.	0.5	0
136	The safety and efficiency of onabotulinumtoxinA for the treatment of overactive bladder: a systematic review and meta-analysis. <i>International Urology and Nephrology</i> , 2015, 47, 1779-1788.	0.6	22

#	ARTICLE	IF	CITATIONS
137	Real-Time Classification of Bladder Events for Effective Diagnosis and Treatment of Urinary Incontinence. IEEE Transactions on Biomedical Engineering, 2015, 63, 1-1.	2.5	27
138	Urinary Biomarkers Under Investigation for Overactive Bladder Syndrome. Current Bladder Dysfunction Reports, 2015, 10, 355-361.	0.2	1
139	Contribution of behavioral and cognitive therapy to managing overactive bladder syndrome in women in the absence of contributive urodynamic diagnosis. International Urogynecology Journal, 2015, 26, 169-173.	0.7	8
140	Severity of Symptoms of Overactive Bladder: A Predictor of Success and of Failure. European Urology, 2015, 67, 15-16.	0.9	1
141	Anticholinergics for overactive bladder: Temporal trends in prescription and treatment persistence. Canadian Urological Association Journal, 2016, 10, 277.	0.3	5
142	New pharmacotherapy for treating overactive bladder: mirabegron and botulinum toxin. Journal of the Korean Medical Association, 2016, 59, 795.	0.1	0
144	Evaluation and management of overactive bladder: strategies for optimizing care. Research and Reports in Urology, 2016, Volume 8, 113-122.	0.6	39
145	Overactive bladder “ 18 years “ Part II. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2016, 42, 199-214.	0.7	13
146	Efficacy of Transcutaneous Electrical Nerve Stimulation in the Treatment of Overactive Bladder. Journal of Clinical and Diagnostic Research JCDR, 2016, 10, QC17-QC20.	0.8	3
147	Intracavitary electrical stimulation as treatment for overactive bladder: systematic review. Fisioterapia Em Movimento, 2016, 29, 813-820.	0.4	0
148	Adverse Events of Intravesical OnabotulinumtoxinA Injection between Patients with Overactive Bladder and Interstitial Cystitis“Different Mechanisms of Action of Botox on Bladder Dysfunction?. Toxins, 2016, 8, 75.	1.5	17
149	Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection in Patients with Detrusor Hyperactivity and Impaired Contractility. Toxins, 2016, 8, 82.	1.5	24
150	Use of Botulinum Toxin A in the Treatment of Lower Urinary Tract Disorders: A Review of the Literature. Toxins, 2016, 8, 88.	1.5	26
151	Persistence and compliance with medication management in the treatment of overactive bladder. Investigative and Clinical Urology, 2016, 57, 84.	1.0	60
152	Persistence of solifenacin therapy in patients with overactive bladder in the clinical setting: a prospective, multicenter, observational study. International Journal of Clinical Practice, 2016, 70, 351-357.	0.8	12
153	Impact of childhood and recent traumatic events on the clinical presentation of overactive bladder. Neurourology and Urodynamics, 2016, 35, 1017-1023.	0.8	38
154	Different number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: A prospective randomized comparative study. Neurourology and Urodynamics, 2016, 35, 717-723.	0.8	24
155	A multiplexed analysis approach identifies new association of inflammatory proteins in patients with overactive bladder. American Journal of Physiology - Renal Physiology, 2016, 311, F28-F34.	1.3	21

#	ARTICLE	IF	CITATIONS
156	The endocannabinoid system " a target for the treatment of LUTS?. Nature Reviews Urology, 2016, 13, 463-470.	1.9	27
157	The Effectiveness of Anticholinergic Therapy for Overactive Bladders: Systematic Review and Meta-Analysis. Revista Brasileira De Ginecologia E Obstetricia, 2016, 38, 564-575.	0.3	4
160	Posterior tibial nerve stimulation in adults with overactive bladder syndrome: A systematic review of the literature. Journal of Clinical Urology, 2016, 9, 120-127.	0.1	2
161	AUA White Paper on the Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. Urology Practice, 2016, 3, 102-111.	0.2	9
162	Overactive Bladder. , 2016, , 251-268.		0
163	Practical points in the medical treatment of overactive bladder andNocturia in the elderly. Tzu Chi Medical Journal, 2016, 28, 1-5.	0.4	3
164	Systemic Nonurological Symptoms in Patients with Overactive Bladder. Journal of Urology, 2016, 196, 467-472.	0.2	17
165	Economic impact of using fesoterodine for the treatment of overactive bladder with urge urinary incontinence in a vulnerable elderly population in the United States. Journal of Medical Economics, 2016, 19, 229-235.	1.0	8
167	A Narrative Review of Patient-reported Outcomes in Overactive Bladder: What is the Way of the Future?. European Urology, 2016, 70, 799-805.	0.9	23
168	Concise Synthesis of Key Intermediate of Mirabegron via a Mixed Anhydride Method. Organic Process Research and Development, 2016, 20, 1993-1996.	1.3	10
169	Antimuscarinic Medication Use in Elderly Patients with Overactive Bladder. Drugs and Aging, 2016, 33, 755-763.	1.3	11
170	Acupuncture for the treatment of overactive bladder: A protocol for systematic review and meta-analysis of randomized controlled trials. European Journal of Integrative Medicine, 2016, 8, 875-878.	0.8	0
171	The Relationship Between Anxiety and Overactive Bladder or Urinary Incontinence Symptoms in the Clinical Population. Urology, 2016, 98, 50-57.	0.5	70
172	Potential benefits of diagnosis and treatment on health outcomes among elderly people with symptoms of overactive bladder. International Journal of Clinical Practice, 2016, 70, 66-81.	0.8	5
173	Urodynamic findings in women with refractory overactive bladder symptoms. International Journal of Urology, 2016, 23, 75-79.	0.5	23
174	The Overactive Bladder and the AUA Guidelines: A Proposed Clinical Pathway for Evaluation and Effective Management in a Contemporary Urology Practice. Urology Practice, 2016, 3, 399-405.	0.2	4
175	Management of refractory overactive bladder. The Obstetrician and Gynaecologist, 2016, 18, 173-181.	0.2	5
176	Combined Tolterodine and Vaginal Estradiol Cream for Overactive Bladder Symptoms After Randomized Single-Therapy Treatment. Female Pelvic Medicine and Reconstructive Surgery, 2016, 22, 254-260.	0.6	18

#	ARTICLE	IF	CITATIONS
177	Differences in the Association of Nocturia and Functional Outcomes of Sleep by Age and Gender: A Cross-sectional, Population-based Study. <i>Clinical Therapeutics</i> , 2016, 38, 2386-2393.e1.	1.1	17
178	The relationship between depression and overactive bladder/urinary incontinence symptoms in the clinical OAB population. <i>BMC Urology</i> , 2016, 16, 60.	0.6	69
179	High satisfaction with direct switching from antimuscarinics to mirabegron in patients receiving stable antimuscarinic treatment. <i>Medicine (United States)</i> , 2016, 95, e4962.	0.4	15
180	Imprisoned in the Cultural Stereotypes of Overactive Bladder. <i>Nursing Research</i> , 2016, 65, 352-361.	0.8	3
181	Multimodal Physical Therapy Intervention for Urinary Incontinence and Overactive Bladder in the Older Adult. <i>Topics in Geriatric Rehabilitation</i> , 2016, 32, 264-273.	0.2	2
182	Management of Urinary and Fecal Incontinence in Patients With Complex Regional Pain Syndrome. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2016, 22, e14-e16.	0.6	2
183	Uso de la onabotulinumtoxina A en pacientes con vejiga hiperactiva idiopática con falta de eficacia, intolerancia o contraindicación para los anticolinérgicos. <i>Urología Colombiana</i> , 2016, 25, 10-15.	0.0	0
184	OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales. <i>European Journal of Health Economics</i> , 2016, 17, 911-921.	1.4	13
185	Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives. <i>Journal of Medical Economics</i> , 2016, 19, 1135-1143.	1.0	23
187	The Burden of Overactive Bladder on US Public Health. <i>Current Bladder Dysfunction Reports</i> , 2016, 11, 8-13.	0.2	93
188	Does central sensitization help explain idiopathic overactive bladder?. <i>Nature Reviews Urology</i> , 2016, 13, 481-491.	1.9	70
189	Therapeutic Potential of Human Chorionic Gonadotropin Against Overactive Bladder. <i>Reproductive Sciences</i> , 2016, 23, 1122-1128.	1.1	2
190	Economic impact of onabotulinumtoxinA for overactive bladder with urinary incontinence in Europe. <i>Journal of Medical Economics</i> , 2016, 19, 1107-1115.	1.0	6
191	Are Bladder Diaries Helpful in Management of Overactive Bladder?. <i>Current Bladder Dysfunction Reports</i> , 2016, 11, 14-17.	0.2	1
192	Indications for Augmentation Cystoplasty in the Era of OnabotulinumtoxinA. <i>Current Urology Reports</i> , 2016, 17, 27.	1.0	26
193	Pelvic Floor Muscle Training: Underutilization in the USA. <i>Current Urology Reports</i> , 2016, 17, 10.	1.0	34
194	OnabotulinumtoxinA Treatment for Overactive Bladder in the Elderly: Practical Points and Future Prospects. <i>Drugs and Aging</i> , 2016, 33, 1-9.	1.3	5
195	A prospective randomized trial comparing the use of tolterodine or weighted vaginal cones in women with overactive bladder syndrome. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2016, 197, 91-97.	0.5	11

#	ARTICLE	IF	CITATIONS
196	Urinary Dysfunction in Prostate Cancer. , 2016, , .		2
197	Overactive Bladder. , 2016, , 33-68.		0
198	Conjoint Urological Society of Australia and New Zealand (<scp>USANZ</scp>) and Urogynaecological Society of Australasia (<scp>UGSA</scp>) Guidelines on the management of adult nonâ€urogenic overactive bladder. BJU International, 2016, 117, 34-47.	1.3	28
199	Vitamin D and incident urinary incontinence in older adults. European Journal of Clinical Nutrition, 2016, 70, 987-989.	1.3	25
200	Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics. Current Medical Research and Opinion, 2016, 32, 621-638.	0.9	58
201	The Role of Mindfulness in Urinary Urgency Symptoms. Current Bladder Dysfunction Reports, 2016, 11, 38-44.	0.2	3
202	Nonantimuscarinic treatment for overactive bladder: aâsystematic review. American Journal of Obstetrics and Gynecology, 2016, 215, 34-57.	0.7	49
203	The Role of Acupuncture in Pain Management. Current Pain and Headache Reports, 2016, 20, 22.	1.3	72
204	Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison. BMJ Open, 2016, 6, e009122.	0.8	14
205	OnabotulinumtoxinA in overactive bladder: Evidence-based consensus recommendations. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2016, 40, 139-147.	0.2	4
206	Contemporary management of acute kidney trauma. Journal of Acute Disease, 2016, 5, 29-36.	0.0	10
207	Impact of Dry Mouth on Fluid Intake and Overactive Bladder Symptoms in Women taking Fesoterodine. Journal of Urology, 2016, 195, 1517-1522.	0.2	6
208	Urinary urgency and frequency in a 53-year-old woman. Cmaj, 2016, 188, 59-60.	0.9	0
209	OnabotulinumtoxinA en vejiga hiperactiva: Recomendaciones de consenso basadas en la evidencia. Actas UrolÃ³gicas EspaÃ±olas, 2016, 40, 139-147.	0.3	4
210	Is Pelvic Floor Muscle Training Effective for Men With Poststroke Lower Urinary Tract Symptoms? A Single-Blinded Randomized, Controlled Trial. American Journal of Men's Health, 2017, 11, 1460-1471.	0.7	19
211	Outcomes of different protocols of pelvic floor physical therapy and antiâ€cholinergics in women with wet overâ€active bladder: A 4â€year followâ€up. Neurourology and Urodynamics, 2017, 36, 755-758.	0.8	20
212	Sacral Neuromodulation in Urological Practice. Urology, 2017, 99, 14-22.	0.5	42
213	Efficacy and Adherence of Flexibly Adding on a Second Antimuscarinic Agent for Patients with Refractory Overactive Bladder. LUTS: Lower Urinary Tract Symptoms, 2017, 9, 27-32.	0.6	14

#	ARTICLE	IF	CITATIONS
214	Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: A randomized crossover study (the MICRO study). <i>Neurourology and Urodynamics</i> , 2017, 36, 1097-1103.	0.8	11
215	Overactive bladder and autonomic dysfunction: Lower urinary tract symptoms in females with postural tachycardia syndrome. <i>Neurourology and Urodynamics</i> , 2017, 36, 610-613.	0.8	18
216	Re: Conjoint Urological Society of Australia and New Zealand (USANZ) and Urogynaecological Society of Australasia (UGSA) Guidelines on the Management of Adult Non-Neurogenic Overactive Bladder. <i>Journal of Urology</i> , 2017, 197, 218-219.	0.2	0
217	A Systematic Approach to the Evaluation and Management of the Failed Artificial Urinary Sphincter. <i>Current Urology Reports</i> , 2017, 18, 18.	1.0	9
219	Pathophysiology of the Underactive Bladder: Evolving New Concepts. <i>Current Bladder Dysfunction Reports</i> , 2017, 12, 35-41.	0.2	6
220	Evidence of the Impact of Diet, Fluid Intake, Caffeine, Alcohol and Tobacco on Lower Urinary Tract Symptoms: A Systematic Review. <i>Journal of Urology</i> , 2017, 198, 1010-1020.	0.2	66
221	Dual Therapy for Refractory Overactive Bladder in Children: A Prospective Open-Label Study. <i>Journal of Urology</i> , 2017, 197, 1158-1163.	0.2	39
222	Urinary retention in female OAB after intravesical Botox injection: who is really at risk?. <i>International Urogynecology Journal</i> , 2017, 28, 845-850.	0.7	38
223	Does physician specialty affect persistence to pharmacotherapy among patients with overactive bladder syndrome?. <i>International Urogynecology Journal</i> , 2017, 28, 409-415.	0.7	5
224	Evaluation and Management of Voiding Dysfunction Following Surgery for Mesh Excision. <i>Current Bladder Dysfunction Reports</i> , 2017, 12, 252-259.	0.2	1
225	The Beneficial Effect of Fesoterodine, a Competitive Muscarinic Receptor Antagonist on Erectile Dysfunction in Streptozotocin-induced Diabetic Rats. <i>Urology</i> , 2017, 107, 271.e1-271.e7.	0.5	3
226	Estimulación transcutánea del nervio tibial posterior en el tratamiento de la incontinencia urinaria de urgencia refractaria, de origen idiopático y neurogénico. <i>Actas Urológicas Españolas</i> , 2017, 41, 465-470.	0.3	23
227	Adding Mirabegron to Solifenacin to Treat Overactive Bladder Has Little Impact on Postvoid Residual Volume or Urinary Retention Risk. <i>Urology</i> , 2017, 104, 1-4.	0.5	5
228	Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis. <i>International Journal of Clinical Practice</i> , 2017, 71, e12824.	0.8	44
231	von Brunn's Nests and Follicular Cystitis Following Intradetrusor OnabotulinumtoxinA Injections for Overactive Bladder. <i>Urology Case Reports</i> , 2017, 14, 38-41.	0.1	7
232	Nocturia is Associated with Poor Sleep Quality Among Older Women in the Study of Osteoporotic Fractures. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 2502-2509.	1.3	14
233	Palliation of Bladder Spasms #337. <i>Journal of Palliative Medicine</i> , 2017, 20, 1158-1159.	0.6	3
234	Transcutaneous stimulation of the posterior tibial nerve for treating refractory urge incontinence of idiopathic and neurogenic origin. <i>Actas Urológicas Españolas (English Edition)</i> , 2017, 41, 465-470.	0.2	7

#	ARTICLE	IF	CITATIONS
235	Frequent nocturia episodes, a suboptimal response to treatment, and small bladder capacity predict the need for persistent antimuscarinic therapy or re-treatment after discontinuation of antimuscarinics in female overactive bladder. <i>Menopause</i> , 2017, 24, 100-104.	0.8	8
236	Quality-of-Life Outcomes Following Surface Electromyography Biofeedback as an Adjunct to Pelvic Floor Muscle Training for Urinary Incontinence: A Case Report. <i>Journal of Women's Health Physical Therapy</i> , 2017, 41, 73-82.	0.5	2
237	The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States. <i>Journal of Medical Economics</i> , 2017, 20, 1272-1280.	1.0	5
238	Overactive bladder treatment: application of methylene blue to improve the injection technique of onabotulinum toxin A. <i>Scandinavian Journal of Urology</i> , 2017, 51, 474-478.	0.6	8
239	Trends in Ambulatory Management of Urinary Incontinence in Women in the United States. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2017, 23, 250-255.	0.6	12
240	Sleep Disturbance and Fatigue Are Associated With More Severe Urinary Incontinence and Overactive Bladder Symptoms. <i>Urology</i> , 2017, 109, 67-73.	0.5	51
241	CE. <i>American Journal of Nursing</i> , 2017, 117, 34-41.	0.2	2
242	Resolution of Overactive Bladder After Mid-Urethral Sling Placement With Mixed Incontinence. <i>Current Bladder Dysfunction Reports</i> , 2017, 12, 80-85.	0.2	0
243	Response to the Letter to the Editor by Arndt van Ophoven. <i>Archives of Gynecology and Obstetrics</i> , 2017, 296, 131-132.	0.8	2
244	Use of Bladder Antimuscarinics in Older Adults with Impaired Cognition. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 390-394.	1.3	19
245	The effect of EMG biofeedback assisted pelvic floor muscle therapy on symptoms of the overactive bladder syndrome in women: A randomized controlled trial. <i>Neurourology and Urodynamics</i> , 2017, 36, 1796-1803.	0.8	45
246	Readability analysis of online health information about overactive bladder. <i>Neurourology and Urodynamics</i> , 2017, 36, 1782-1787.	0.8	14
247	A systematic review of the literature on disorders of sleep and wakefulness in Parkinson's disease from 2005 to 2015. <i>Sleep Medicine Reviews</i> , 2017, 35, 33-50.	3.8	240
248	Comparison of the effectiveness of repeated injections of onabotulinum toxin A for refractory idiopathic detrusor overactivity: analysis of an open label extension of a randomized trial (the RELAX) Tj ETQq1 1 0.784314 r8BT /Over	0.8	8
249	Effect of anticholinergic burden on the development of dementia in older adults with subjective cognitive decline. <i>Journal of Theoretical Social Psychology</i> , 2017, 27, 263-270.	1.2	7
250	Urodynamic Testing: Choosing Between Simple Versus Complex. <i>Current Obstetrics and Gynecology Reports</i> , 2017, 6, 269-273.	0.3	0
251	Percutaneous tibial nerve stimulation versus electrical stimulation with pelvic floor muscle training for overactive bladder syndrome in women: results of a randomized controlled study. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2017, 43, 121-126.	0.7	40
252	Urogynecological conditions associated with overactive bladder symptoms in women. <i>Canadian Urological Association Journal</i> , 2017, 11, 83.	0.3	6

#	ARTICLE	IF	CITATIONS
253	Management of overactive bladder review: the role of percutaneous tibial nerve stimulation. Medical Journal of Indonesia, 2017, 25, 245-54.	0.2	0
254	β ₃ -AR Agonists for the Treatment of Overactive Bladder. , 2017, , 714-737.		1
255	Recent advances in pharmacological management of urinary incontinence. F1000Research, 2017, 6, 2148.	0.8	4
256	Physiotherapy in Women with Urinary Incontinence. , 0, , .		2
257	Use of botulinum toxin for voiding dysfunction. Translational Andrology and Urology, 2017, 6, 234-251.	0.6	11
258	Best practice in the management of storage symptoms in male lower urinary tract symptoms: a review of the evidence base. Therapeutic Advances in Urology, 2018, 10, 79-92.	0.9	31
259	Acupuncture for adults with overactive bladder. Medicine (United States), 2018, 97, e9838.	0.4	20
260	Prospective randomized study evaluating ultrasound versus fluoroscopy guided sacral InterStim® lead placement: A pilot study. Neurourology and Urodynamics, 2018, 37, 1737-1743.	0.8	10
261	Is it Safe to Reduce Water Intake in the Overactive Bladder Population? A Systematic Review. Journal of Urology, 2018, 200, 375-381.	0.2	8
262	Overactive Bladder and Lifestyle Factors. Journal of Women's Health, 2018, 27, 121-122.	1.5	0
263	Effects of Bladder Training and Pelvic Floor Muscle Training in Female Patients with Overactive Bladder Syndrome: A Randomized Controlled Trial. Urologia Internationalis, 2018, 100, 420-427.	0.6	22
264	Validación de la versión española del cuestionario Bladder Pain/Interstitial Cystitis-Symptom Score (BPIC-SS). Un instrumento útil para el diagnóstico del síndrome de dolor vesical. Actas Urológicas Españolas, 2018, 42, 457-464.	0.3	4
265	The history of the Society of Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction. Neurourology and Urodynamics, 2018, 37, 2015-2025.	0.8	1
266	Efficacy of pelvic floor muscle training in women with overactive bladder syndrome: a systematic review. International Urogynecology Journal, 2018, 29, 1565-1573.	0.7	27
267	Failures of Sacral Neuromodulation for Incontinence. JAMA Surgery, 2018, 153, 493.	2.2	9
268	Urodynamics. , 0, , 207-223.		0
269	Acupuncture for management of lower urinary tract symptoms in Parkinson's disease. Medicine (United States), 2018, 97, e9821.	0.4	3
270	Development of an overactive bladder assessment tool (BAT): A potential improvement to the standard bladder diary. Neurourology and Urodynamics, 2018, 37, 1701-1710.	0.8	5

#	ARTICLE	IF	CITATIONS
271	Comparison of 3 Different Teaching Methods for a Behavioral Therapy Program for Female Overactive Bladder. <i>Journal of Wound, Ostomy and Continence Nursing</i> , 2018, 45, 68-74.	0.6	10
272	Overactive Bladder Syndrome: Evaluation and Management. <i>Current Urology</i> , 2018, 11, 117-125.	0.4	79
274	A prospective study of elderly initiating mirabegron versus antimuscarinics: Patient reported outcomes from the Overactive Bladder Satisfaction Scales and other instruments. <i>Neurourology and Urodynamics</i> , 2018, 37, 177-185.	0.8	5
275	Structured behavioral treatment research protocol for women with mixed urinary incontinence and overactive bladder symptoms. <i>Neurourology and Urodynamics</i> , 2018, 37, 14-26.	0.8	27
276	Costs and Sustainability of a Behavioral Intervention for Urinary Incontinence Prevention. <i>Urology Practice</i> , 2018, 5, 266-271.	0.2	0
277	What is the true catheterization rate after intravesical onabotulinumtoxinA injection?. <i>International Urogynecology Journal</i> , 2018, 29, 1005-1009.	0.7	21
278	Trends and Clinical Practice Patterns of Sacral Neuromodulation for Overactive Bladder. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2018, 24, 264-266.	0.6	4
280	Effectiveness and safety of moxibustion for alleviating symptoms of overactive bladder. <i>Medicine (United States)</i> , 2018, 97, e12016.	0.4	9
281	Salvage Combination Therapies for Refractory Overactive Bladder. <i>Current Bladder Dysfunction Reports</i> , 2018, 13, 301-308.	0.2	2
282	Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom. <i>PLoS ONE</i> , 2018, 13, e0204456.	1.1	15
283	PATHOPHYSIOLOGY, MECHANISM AND MANAGEMENT OF OVERACTIVE BLADDER SYNDROME-A REVIEW. <i>International Journal of Pharmacy and Pharmaceutical Sciences</i> , 2018, 10, 1.	0.3	0
284	Management of Overactive Bladder Symptoms After Radical Prostatectomy. <i>Current Urology Reports</i> , 2018, 19, 95.	1.0	21
285	The LURN Research Network Neuroimaging and Sensory Testing (NIST) Study: Design, protocols, and operations. <i>Contemporary Clinical Trials</i> , 2018, 74, 76-87.	0.8	7
286	Recurrent Urinary Tract Infections in Females and the Overlap with Overactive Bladder. <i>Current Urology Reports</i> , 2018, 19, 94.	1.0	20
287	Electroacupuncture to treat with Overactive Bladder in Postmenopausal Women: study protocol for a multicenter, randomized, controlled, parallel clinical trial. <i>Trials</i> , 2018, 19, 493.	0.7	0
288	Complications of Botox and their Management. <i>Current Urology Reports</i> , 2018, 19, 90.	1.0	11
289	Management of Overactive Bladder in Older Women. <i>Current Urology Reports</i> , 2018, 19, 92.	1.0	30
290	Re: Use of Bladder Antimuscarinics in Older Adults with Impaired Cognition. <i>Journal of Urology</i> , 2018, 200, 475-478.	0.2	0

#	ARTICLE	IF	CITATIONS
291	Position statement: a clinical approach to the management of adult non-neurogenic overactive bladder. <i>Medical Journal of Australia</i> , 2018, 208, 41-45.	0.8	11
292	Validation of the Spanish version of the Bladder Pain/Interstitial Cystitis-Symptom Score (BPIC-SS) questionnaire. A useful tool for the diagnosis of bladder pain syndrome. <i>Actas Urológicas Españolas (English Edition)</i> , 2018, 42, 457-464.	0.2	1
293	Stress Urinary Incontinence Management in the Patient With Overactive Bladder. <i>Current Bladder Dysfunction Reports</i> , 2018, 13, 111-117.	0.2	0
294	Metabolomic Analysis of Overactive Bladder in Male Patients: Identification of Potential Metabolite Biomarkers. <i>Urology</i> , 2018, 118, 158-163.	0.5	8
295	Recurrent Pelvic Organ Prolapse. , 2018, , .		1
296	Troubleshooting Interstim Sacral Neuromodulation Generators to Recover Function. <i>Current Urology Reports</i> , 2018, 19, 86.	1.0	17
297	Fibroid surgery and improvement in bladder symptoms: The FAB study. <i>Neurourology and Urodynamics</i> , 2018, 37, 1965-1970.	0.8	9
298	Current Therapeutic Strategies in Clinical Urology. <i>Molecular Pharmaceutics</i> , 2018, 15, 3010-3019.	2.3	6
299	Comparaçãõ entre oxibutinina, eletroestimulaçãõ do nervo tibial posterior e exercÃcios perineais no tratamento da sÃndrome da bexiga hiperativa. <i>Fisioterapia E Pesquisa</i> , 2019, 26, 127-136.	0.3	5
300	Editorial Comment. <i>Urology</i> , 2019, 130, 28.	0.5	0
301	Is nocturnal enuresis a predisposing factor for the overactive bladder?. <i>Turkish Journal of Medical Sciences</i> , 2019, 49, 703-709.	0.4	1
303	Women With Overactive Bladder Exhibit More Unhealthy Toileting Behaviors: A Cross-sectional Study. <i>Urology</i> , 2019, 134, 97-102.	0.5	7
304	Is the development of clinical practice guidelines for non-neurogenic overactive bladder trustworthy? A critical appraisal using the Appraisal of Guidelines, Research and Evaluation (AGREE) II instrument. <i>BJU International</i> , 2019, 123, 921-922.	1.3	7
305	Intra-bladder wall transplantation of bone marrow mesenchymal stem cells improved urinary bladder dysfunction following spinal cord injury. <i>Life Sciences</i> , 2019, 221, 20-28.	2.0	18
306	Recent Non-neurogenic Overactive Bladder Trials. <i>Current Bladder Dysfunction Reports</i> , 2019, 14, 18-23.	0.2	1
307	Development of an online personalized self-management intervention for men with uncomplicated LUTS. <i>Neurourology and Urodynamics</i> , 2019, 38, 1685-1691.	0.8	4
308	Factors associated with overactive bladder symptom improvement after 1 year of monthly percutaneous tibial nerve stimulation therapy. <i>Neurourology and Urodynamics</i> , 2019, 38, 1676-1684.	0.8	6
309	Outcomes for Intravesical Abobotulinumtoxin A (Dysport) Treatment in the Active Management of Overactive Bladder Symptoms: A Prospective Study. <i>Urology</i> , 2019, 130, 54-58.	0.5	8

#	ARTICLE	IF	CITATIONS
310	Relative Risk of Adverse Events and Treatment Discontinuations Between Older and Non-Older Adults Treated with Antimuscarinics for Overactive Bladder: A Systematic Review and Meta-Analysis. <i>Drugs and Aging</i> , 2019, 36, 639-645.	1.3	9
311	The Distribution of Post-Void Residual Volumes in People Seeking Care in the Symptoms of Lower Urinary Tract Dysfunction Network Observational Cohort Study With Comparison to Asymptomatic Populations. <i>Urology</i> , 2019, 130, 22-28.	0.5	5
312	Acoustoelasticity Analysis of Transient Waves for Non-Invasive In Vivo Assessment of Urinary Bladder. <i>Scientific Reports</i> , 2019, 9, 2441.	1.6	10
313	A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment. <i>European Urology</i> , 2019, 75, 988-1000.	0.9	196
314	What uro-gynecologists should know about sacral neuromodulation (SNM) for the treatment of refractory overactive bladder. <i>Archives of Gynecology and Obstetrics</i> , 2019, 299, 1243-1252.	0.8	5
315	Transvaginal ultrasound guided trigone and bladder injection: A cadaveric feasibility study for a novel route of intradetrusor chemodenervation. <i>Investigative and Clinical Urology</i> , 2019, 60, 40.	1.0	6
316	Audiovisual stimulus during urodynamics to provoke detrusor overactivity: A randomized trial. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2019, 11, 127-132.	0.6	2
317	Overnight Urge Perception in Nocturia Is Independent of Depression, PTSD, or Anxiety in a Male Veterans Administration Population. <i>Journal of Clinical Sleep Medicine</i> , 2019, 15, 615-621.	1.4	3
318	Pharmacologic and Nonpharmacologic Treatments for Urinary Incontinence in Women. <i>Annals of Internal Medicine</i> , 2019, 170, 465.	2.0	48
319	Association of Anticholinergic Risk Score With Functional Status in Patients Preparing for Pelvic Reconstructive Surgery. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2019, 25, 453-456.	0.6	0
320	Urinary Incontinence in Elderly Men: Update on Evaluation and Treatment. <i>Current Geriatrics Reports</i> , 2019, 8, 322-330.	1.1	4
321	Magnetic stimulation for female patients with stress urinary incontinence, a meta-analysis of studies with short-term follow-up. <i>Medicine (United States)</i> , 2019, 98, e15572.	0.4	21
322	Role of the Wound, Ostomy and Continence Nurse in Continence Care: 2018 Update. <i>Journal of Wound, Ostomy and Continence Nursing</i> , 2019, 46, 221-225.	0.6	5
323	Higher urge severity score predicts resumption of overactive bladder (OAB) medication following discontinuation of mirabegron treatment in patients with OAB. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2019, 11, O180-O185.	0.6	4
324	Etiology of nocturia response in men with diminished bladder capacity. <i>Neurourology and Urodynamics</i> , 2019, 38, 215-222.	0.8	9
325	Cost-effectiveness of overactive bladder treatments: from the US payer perspective. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 61-71.	0.6	25
326	Systematic Review of Combination Drug Therapy for Non-neurogenic Lower Urinary Tract Symptoms. <i>European Urology</i> , 2019, 75, 129-168.	0.9	19
327	Symptomatic overlap in overactive bladder and interstitial cystitis/bladder pain syndrome: development of a new algorithm. <i>BJU International</i> , 2019, 123, 682-693.	1.3	22

#	ARTICLE	IF	CITATIONS
328	Differential Nocturnal Diuresis Rates Among Patients with and Without Nocturnal Polyuria Syndrome. <i>European Urology Focus</i> , 2020, 6, 320-326.	1.6	7
329	Urological Care for Patients with Progressive Neurological Conditions. , 2020, , .		0
330	Interventions for Overactive Bladder: Review of Pelvic Floor Muscle Training and Urgency Control Strategies. <i>Journal of Women's Health Physical Therapy</i> , 2020, 44, 19-25.	0.5	8
331	Gender specific pharmacokinetic and pharmacodynamic considerations for antimuscarinic drugs for overactive bladder treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 103-110.	1.5	7
332	Traumatic Kidney Injury: An Observational Descriptive Study. <i>Urologia Internationalis</i> , 2020, 104, 148-155.	0.6	9
333	Fibroid Surgery and Long-Term Improvement in Bladder Symptoms. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2020, 42, 131-136.	0.3	3
334	Longitudinal changes in symptomâ€based female and male LUTS clusters. <i>Neurourology and Urodynamics</i> , 2020, 39, 393-402.	0.8	6
335	Statewide Success of Staged Sacral Neuromodulation for the Treatment of Urinary Complaints in California (2005â€2011). <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2020, 26, 437-442.	0.6	16
336	Increasing Age Predicts Increasing Residual Urine Volume. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2020, 26, 769-773.	0.6	1
337	Effect of electroacupuncture versus solifenacin for moderate and severe overactive bladder: a multi-centre, randomized controlled trial study protocol. <i>BMC Complementary Medicine and Therapies</i> , 2020, 20, 224.	1.2	2
338	The Role of Urodynamic Testing Prior to Third-Line OAB Therapy. <i>Current Bladder Dysfunction Reports</i> , 2020, 15, 159-165.	0.2	0
339	Acupuncture for postprostatectomy incontinence: a systematic review. <i>BMJ Supportive and Palliative Care</i> , 2023, 13, e10-e19.	0.8	4
340	Assessment of patients with lower urinary tract symptoms where an undiagnosed neurological disease is suspected: A report from an International Continence Society consensus working group. <i>Neurourology and Urodynamics</i> , 2020, 39, 2535-2543.	0.8	18
341	Increased Healthcare Resource Utilization and Direct and Indirect Costs in Patients with Depression and Comorbid Overactive Bladder: Evidence From a Retrospective, Matched Caseâ€Control Cohort Analysis. <i>Advances in Therapy</i> , 2020, 37, 4599-4613.	1.3	2
342	Compliance to Individualized Recommendations Based on an Evidence-Based Algorithm for Behavioral Management of Lower Urinary Tract Symptoms. <i>Journal of Wound, Ostomy and Continence Nursing</i> , 2020, 47, 381-387.	0.6	3
343	Urodynamics for the â€Failedâ€Midurethral Sling. <i>Current Bladder Dysfunction Reports</i> , 2020, 15, 245-258.	0.2	3
347	Racial and Socioeconomic Factors Influence Utilization of Advanced Therapies in Commercially Insured OAB Patients: An Analysis of Over 800,000 OAB Patients. <i>Urology</i> , 2020, 142, 81-86.	0.5	18
348	A prospective observational cohort study of posterior tibial nerve stimulation in patients with multiple sclerosis: design and methods. <i>BMC Urology</i> , 2020, 20, 58.	0.6	6

#	ARTICLE	IF	CITATIONS
349	The clinical pharmacology of the medical treatment for overactive bladder in adults. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 707-720.	1.3	8
350	Functional atropine sensitive purinergic responses in the healthy rat bladder. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2020, 227, 102693.	1.4	3
351	Practice Patterns for Women With Overactive Bladder Syndrome: Time Between Medications and Third-Line Treatments. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2020, 26, 431-436.	0.6	15
352	Bioinformatics Approach for Identifying Novel Biomarkers and Their Signaling Pathways Involved in Interstitial Cystitis/Bladder Pain Syndrome with Hunner Lesion. <i>Journal of Clinical Medicine</i> , 2020, 9, 1935.	1.0	15
353	Systematic review of guidelines for urinary incontinence in women. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2020, 49, 101842.	0.6	10
354	A randomized, crossover trial comparing the efficacy and safety of fesoterodine and extended-release oxybutynin in children with overactive bladder with 12-month extension on fesoterodine: The FOXY study. <i>Canadian Urological Association Journal</i> , 2020, 14, 192-198.	0.3	7
355	A randomized, controlled trial of transcutaneous tibial nerve stimulation to treat overactive bladder and neurogenic bladder patients. <i>Canadian Urological Association Journal</i> , 2020, 14, E297-E303.	0.3	12
356	Overactive Bladder in Women: an Update for Primary Care Physicians. <i>Current Bladder Dysfunction Reports</i> , 2020, 15, 44-52.	0.2	0
357	Meta-Analysis of Randomized Controlled Trials Using Botulinum Toxin A at Different Dosages for Urinary Incontinence in Patients With Overactive Bladder. <i>Frontiers in Pharmacology</i> , 2019, 10, 1618.	1.6	14
358	Stimulation of the pelvic nerve increases bladder capacity in the PGE ₂ cat model of overactive bladder. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, F1357-F1368.	1.3	4
359	Fall/Fracture-Related Healthcare Costs and Their Association with Cumulative Anticholinergic Burden in People with Overactive Bladder. <i>PharmacoEconomics - Open</i> , 2021, 5, 45-55.	0.9	9
360	Evaluation of pupil responses and anterior chamber parameters in overactive bladder syndrome before and after antimuscarinic treatment. <i>Eye</i> , 2021, 35, 1450-1458.	1.1	2
361	A retrospective longitudinal evaluation of new overactive bladder patients in an FPMRS urologist practice: Are patients following up and utilizing third-line therapies?. <i>Neurourology and Urodynamics</i> , 2021, 40, 391-396.	0.8	7
362	The use of vaginal lasers in the treatment of urinary incontinence and overactive bladder, systematic review. <i>International Urogynecology Journal</i> , 2021, 32, 553-572.	0.7	12
363	Effect of diet on storage symptoms in male lower urinary tract symptoms. , 2021, , 177-187.		0
364	Variable- versus constant-frequency sacral neuromodulation in black-zone overactive bladder patients: a study protocol for a multicenter, prospective, randomized, blind, self-controlled trial. <i>Translational Andrology and Urology</i> , 2021, 10, 504-511.	0.6	3
365	Beyond botulinum neurotoxin A for chemodenervation of the bladder. <i>Current Opinion in Urology</i> , 2021, 31, 140-146.	0.9	6
366	Promoting patient followup treatment with intra-detrusor onabotulinumtoxinA. <i>Canadian Urological Association Journal</i> , 2021, 15, E405-E411.	0.3	0

#	ARTICLE	IF	CITATIONS
367	Therapy of Sleep Disorders in Parkinsonâ€™s Disease. , 2021, , 1-20.		0
368	Real-life patient experiences of TTNS in the treatment of overactive bladder syndrome. Therapeutic Advances in Urology, 2021, 13, 175628722110414.	0.9	5
369	Mixed Urinary Incontinence: Strategic Approach. , 2021, , 95-105.		0
370	Cognitive components of behavioral therapy for overactive bladder: a systematic review. International Urogynecology Journal, 2021, 32, 2619-2629.	0.7	7
371	Efficacy of Daily Intake of Dried Cranberry 500 mg in Women with Overactive Bladder: A Randomized, Double-Blind, Placebo Controlled Study. Journal of Urology, 2021, 205, 507-513.	0.2	2
372	Social media analytics of overactive bladder posts: what do patients know and want to know?. International Urogynecology Journal, 2021, 32, 2729-2736.	0.7	7
373	Clustering of patients with overactive bladder syndrome. BMC Urology, 2021, 21, 41.	0.6	4
374	A Clinical Conundrum: The Pharmacistâ€™s Role in Evaluating Comorbid Urinary Incontinence and Heart Failure. , 2021, 36, 142-146.		0
375	Comparison of 100 U With 200 U of Intradetrusor OnabotulinumToxinA for Nonneurogenic Urgency Incontinence. Female Pelvic Medicine and Reconstructive Surgery, 2021, 27, 140-146.	0.6	2
376	The effect of a counseling and training program on the treatment of women with overactive bladder. Psychology, Health and Medicine, 2021, , 1-13.	1.3	3
377	Adult female urinary incontinence guidelines: a systematic review of evaluation guidelines across clinical specialties. International Urogynecology Journal, 2021, 32, 2671-2691.	0.7	1
379	Cannabinoid Therapy in Female Pelvic Medicine and Reconstructive Surgery: Current Evidence and Future Directions. Current Bladder Dysfunction Reports, 2021, 16, 64-73.	0.2	0
380	Review of the rechargeable sacral neuromodulation system to treat refractory overactive bladder. Therapeutic Delivery, 2021, 12, 353-362.	1.2	0
381	Impact of preoperative pelvic floor muscle training (pretraining) on urinary storage and emptying symptoms in women undergoing sling surgery. International Urogynecology Journal, 2021, , 1.	0.7	2
382	Gene Therapy for Overactive Bladder: A Review of BK-Channel β -Subunit Gene Transfer. Therapeutics and Clinical Risk Management, 2021, Volume 17, 589-599.	0.9	11
383	Voiding behavior in awake unrestrained untethered spontaneously hypertensive and Wistar control rats. American Journal of Physiology - Renal Physiology, 2021, 321, F195-F206.	1.3	2
384	Diagnosis and Non-Surgical Management of Urinary Incontinence â€“ A Literature Review with Recommendations for Practice. International Journal of General Medicine, 2021, Volume 14, 4555-4565.	0.8	9
385	Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison. Advances in Therapy, 2021, 38, 5452-5464.	1.3	16

#	ARTICLE	IF	CITATIONS
386	International Continence Society white paper on ethical considerations in older adults with urinary incontinence. <i>Neurourology and Urodynamics</i> , 2022, 41, 14-30.	0.8	9
387	Compensatory bladder behaviors (â€œcopingâ€œ) in women with overactive bladder. <i>Neurourology and Urodynamics</i> , 2022, 41, 195-202.	0.8	4
388	Overactive Bladder: Where We Are and Where We Are Going. <i>Societ� Internationale D'urologie Journal</i> , 2021, , 311-322.	0.2	0
389	Care of Transgender Patients: Incontinence. , 2021, , 203-217.		0
390	Efficacy of 0.4â€œmg tamsulosin monotherapy in patients with moderate-to-severe lower urinary tract symptoms. <i>SAGE Open Medicine</i> , 2021, 9, 205031212110473.	0.7	0
391	Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged â€œ65 and â€œ75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study. <i>Drugs and Aging</i> , 2021, 38, 137-146.	1.3	17
392	Basic Evaluation of the Patient with Pelvic Floor Dysfunction (General Review). , 2021, , 3-16.		0
393	Neural Prosthesis for Neurotrauma. , 2016, , 457-478.		1
394	Clinical Use of Botulinum Neurotoxin: Urogenital Disorders Including Overactive Bladder. , 2014, , 123-152.		1
395	Sacral Neuromodulation. , 2015, , 55-71.		2
396	Cost-Effectiveness of Sacral Neuromodulation versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: Results of the ROSETTA Randomized Trial. <i>Journal of Urology</i> , 2020, 203, 969-977.	0.2	26
397	Report and Research Agenda of the American Geriatrics Society and National Institute on Aging Bedsideâ€œBench Conference on Urinary Incontinence in Older Adults: A Translational Research Agenda for a Complex Geriatric Syndrome. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 773-782.	1.3	34
398	<i>Enterococcus faecalis</i> Subverts and Invades the Host Urothelium in Patients with Chronic Urinary Tract Infection. <i>PLoS ONE</i> , 2013, 8, e83637.	1.1	80
399	Noninvasive Evaluation of Bladder Wall Mechanical Properties as a Function of Filling Volume: Potential Application in Bladder Compliance Assessment. <i>PLoS ONE</i> , 2016, 11, e0157818.	1.1	37
400	A Study on Korean Medical Clinical Management of Female Overactive Bladder. <i>The Journal of Korean Obstetrics and Gynecology</i> , 2014, 27, 83-102.	0.4	4
401	When should we use urodynamic testing? Recommendations of the Italian Society of Urodynamics (SIUD). Part 2 - Male and neurological population. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 187-199.	3.9	5
402	Not all neurogenic bladders are the same: a proposal for a new neurogenic bladder classification system. <i>Translational Andrology and Urology</i> , 2016, 5, 12-21.	0.6	19
403	Clinical evaluation of urinary incontinence. <i>Journal of Mid-Life Health</i> , 2018, 9, 55.	0.4	2

#	ARTICLE	IF	CITATIONS
404	Recent research on the role of urodynamic study in the diagnosis and treatment of male lower urinary tract symptoms and urinary incontinence. Tzu Chi Medical Journal, 2017, 29, 72.	0.4	4
405	Patient treatment preferences for symptomatic refractory urodynamic idiopathic detrusor overactivity. Urology Annals, 2017, 9, 249.	0.3	5
406	Urodynamic characteristics of lower urinary tract of patients with idiopathic overactive bladder. Urology Annals, 2019, 11, 83.	0.3	3
407	Role of percutaneous posterior tibial nerve stimulation either alone or combined with an anticholinergic agent in treating patients with overactive bladder. Turkish Journal of Urology, 2015, 41, 208-214.	1.3	12
408	Eight-Year Experience With Botulinum Toxin Type-A Injections for the Treatment of Nonneurogenic Overactive Bladder: Are Repeated Injections Worthwhile?. International Neurourology Journal, 2006, 20, 40-46.	0.5	3
409	Assessment of Anticholinergic Use After Fading of BTX-A Effects in Refractory Idiopathic Overactive Bladder: A Prospective Blinded Randomized Trial. International Neurourology Journal, 2019, 23, 240-248.	0.5	5
410	Cycling Versus Continuous Mode In Neuromodulator Programming: A Crossover, Randomized, Controlled Trial. Urologic Nursing, 2016, 36, 123.	0.1	7
411	A Systematic Review of Racial/Ethnic Disparities in Female Pelvic Floor Disorders. Urology, 2022, 163, 8-15.	0.5	19
412	Peroneal Electric Transcutaneous NeuroModulation (eTNM [®]): A Novel Method for the Treatment of the Overactive Bladder. Journal of Healthcare Engineering, 2021, 2021, 1-12.	1.1	5
413	The patient pathway for overactive bladder management: A quantitative analysis. Neurourology and Urodynamics, 2022, 41, 290-295.	0.8	3
414	Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial. Blood Pressure Monitoring, 2022, 27, 128-134.	0.4	6
415	Trigonal-Sparing vs. Trigonal-Involved OnabotulinumtoxinA Injection for the Treatment of Overactive Bladder: A Systematic Review and Meta-Analysis. Frontiers in Neurology, 2021, 12, 651635.	1.1	5
416	Urinary Incontinence: Evaluation and Diagnosis. , 2014, , 127-140.		0
418	Augmentation Cystoplasty. , 2015, , 179-192.		1
419	Overactive Bladder. , 2015, , 51-59.		0
420	Novelty in the diagnosis of overactive bladder. Russian Bulletin of Obstetrician-Gynecologist, 2015, 15, 18.	0.0	0
421	Specific features of therapy for disordered urination in menopausal women. Russian Bulletin of Obstetrician-Gynecologist, 2015, 15, 29.	0.0	2
423	Diagnostic and prognostic possibilities of ultrasound study in patients with overactive bladder. Russian Bulletin of Obstetrician-Gynecologist, 2015, 15, 24.	0.0	1

#	ARTICLE	IF	CITATIONS
424	Intravesical Sodium Chondroitin Sulphate to Treat Overactive Bladder: Preliminary Result. International Neurourology Journal, 2015, 19, 85-89.	0.5	1
425	Reoperative Anti-incontinence Surgery. , 2016, , 125-135.		0
426	Efficacy and safety of onabotulinum toxin A for overactive bladder. World Journal of Clinical Urology, 2016, 5, 75.	0.0	0
427	Overactive-Bladder-Syndrom bei Frauen. , 2016, , 871-875.		0
428	Affective Temperament Profiles of Overactive Bladder Patients. Noropsikiyatri Arsivi, 2016, 53, 286-287.	0.7	1
429	Comparing the Effect of Tolterodine, Biofeedback (Pelvic Floor Muscles Training) and Drug plus Biofeedback on Quality of Life and Urge Urinary Incontinency in Patients Referred to Imam Khomeini Hospital in 2014. Journal of Obstetrics, Gynecology and Cancer Research, 2016, 1, 0-0.	0.0	0
430	Overactive Bladder: Non-neurogenic. , 2017, , 21-26.		0
431	Cost Utility Analysis of Sacral Neuro-Modulation vs Botox A in the Treatment of Overactive Bladder in Colombia. Urology & Nephrology Open Access Journal, 2016, 3, .	0.1	0
432	Overactive Bladder: Changing Paradigms in Current Guidelines and Pharmacotherapy. Annals of SBV, 2017, 6, 15-20.	0.0	0
433	Very Low, Real-Time Rate of Urinary Retention after Intradetrusor Botox^{reg}®</sup> for Non-Neurogenic Overactive Bladder. Open Journal of Obstetrics and Gynecology, 2017, 07, 915-921.	0.1	0
434	Typology of urination disorders in patients with idiopathic overactive bladder. Health of Man, 2017, .	0.1	0
435	Urinary Incontinence (UI). , 2017, , .		0
436	Sacral Neuromodulation for Overactive Bladder. , 2018, , 25-46.		2
437	Evaluation of idiopathic overactive urinary bladder treatment with method of biofeedback. Health of Man, 2018, .	0.1	0
438	The Placebo Effect in Overactive Bladder Syndrome. , 2019, , 27-45.		0
439	Complications of Transobturator Synthetic Slings. , 2019, , 243-262.		0
440	Urodynamic patterns of an idiopathic overactive bladder. Urology, 2018, 21, .	0.1	0
441	A rare case report of levofloxacin- and solifenacin-induced acute anaphylactic reaction in an elderly patient. Journal of Mahatma Gandhi Institute of Medical Sciences, 2019, 24, 101.	0.1	0

#	ARTICLE	IF	CITATIONS
442	Methods of Biofeedback as a Factor in Improving the Effectiveness of Correction Functional Disadaptation of the Muscles Pelvic Floor in Patients with Non-neurogenic Hyperactive Bladder. Health of Man, 2019, .	0.1	0
443	The Urologic Management of Huntington Chorea. , 2020, , 105-115.		0
444	The use of botulinum toxin for the treatment of patients with overactive bladder. Pomeranian Journal of Life Sciences, 2019, 64, 9-13.	0.1	0
445	Overactive bladder in an integrated delivery system: a longitudinal cohort study. BMC Health Services Research, 2020, 20, 447.	0.9	2
446	Cognitive-behavioral therapy and urge urinary incontinence in women. A systematic review. International Urogynecology Journal, 2022, 33, 1091-1101.	0.7	5
447	Catgut Implantation at Baliao and Xingfu One Acupuncture Point to Treat Dysdefecation in Patients with Incomplete Spinal Cord Injury: Three Cases Report. Open Journal of Urology, 2020, 10, 211-216.	0.0	0
449	Overactive Bladder. , 2020, , 287-307.		0
450	Therapeutic efficacy of mirabegron 25 mg monotherapy in patients with nocturia-predominant hypersensitive bladder. Tzu Chi Medical Journal, 2020, 32, 30.	0.4	1
452	Effect of Motor Imagery Training on Urinary Incontinence in Patients with Incomplete Spinal Cord Injury. Medical Journal of the University of Cairo Faculty of Medicine, 2020, 88, 869-873.	0.0	0
453	Impact of urodynamic evaluation on the treatment of women with idiopathic overactive bladder: a systematic review. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 420-426.	3.9	7
454	Urodynamic Parameters in Spinal Cord Injury-Induced Neurogenic Bladder Rats after Stem Cell Transplantation: A Narrative Review. Iranian Journal of Medical Sciences, 2020, 45, 2-15.	0.3	14
455	Efficacy and safety of Baweidi Huang-wan in women with overactive bladder: a randomized, double blind, placebo controlled trial. International Journal of Clinical and Experimental Medicine, 2014, 7, 2744-53.	1.3	3
456	Prevalence of overactive bladder syndrome (OABS) among women with gynaecological problems and its risk factors in a tertiary hospital, Negeri Sembilan, Malaysia: Implication for primary healthcare providers. Malaysian Family Physician, 2015, 10, 2-8.	0.2	2
457	Evaluating Outcomes in Patients with Overactive Bladder within an Integrated Healthcare Delivery System Using a Treatment Patterns Analyzer. American Health and Drug Benefits, 2016, 9, 343-353.	0.5	4
458	Cycling Versus Continuous Mode In Neuromodulator Programming: A Crossover, Randomized, Controlled Trial. Urologic Nursing, 2016, 36, 123-32.	0.1	3
459	Overactive bladder syndrome in nulliparous female university students: prevalence and risk factors including waterpipe smoking. International Urogynecology Journal, 2022, 33, 1207-1223.	0.7	2
461	Predicting outcomes after intradetrusor onabotulinumtoxinA for non-neurogenic urgency incontinence in women. Neurourology and Urodynamics, 2022, 41, 432-447.	0.8	9
462	Comparative persistence, switch rates, and predictors for discontinuation of antimuscarinics for overactive bladder: A 10-year nationwide population-based study in Taiwan. Urological Science, 2018, 29, 223.	0.2	2

#	ARTICLE	IF	CITATIONS
464	Treatment of bladder dysfunction with solifenacin: is there a risk of dementia or cognitive impairment?. Brazilian Journal of Medical and Biological Research, 2022, 55, e11721.	0.7	2
465	Incomplete bladder emptying and urinary tract infections after botulinum toxin injection for overactive bladder: Multi-institutional collaboration from the SUFU research network. Neurourology and Urodynamics, 2022, 41, 662-671.	0.8	10
466	Overactive bladder medication prescription trends from 2014 to 2018. Neurourology and Urodynamics, 2022, , .	0.8	5
467	Overactive bladder medication: Anticholinergics versus mirabegron by specialty. Urologia, 2022, 89, 511-516.	0.3	3
468	An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive Bladder. Therapeutics and Clinical Risk Management, 2022, Volume 18, 171-182.	0.9	2
469	Asynchronous telehealth visits for the treatment of overactive bladder. Menopause, 2022, 29, 723-727.	0.8	1
470	A Community-Based Education Program for Overactive Bladder in a Predominantly Minority Older Female Population: A Pilot Study. Urologia Internationalis, 2022, 106, 664-671.	0.6	1
471	Why Patients Fall Through the Cracks: Assessment of Patients' Overactive Bladder Treatment. Journal of Women's Health, 2022, 31, 1314-1319.	1.5	3
472	Challenges and New Insights in the Management of Urinary Incontinence in Older Women. Current Geriatrics Reports, 0, , 1.	1.1	2
473	RESPONSE TO THE AUTHORS "Intravaginal electrical stimulation for bladder training method" by C. J. L. Z. Ricetto, 2021. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2022, 48, 375-376.	0.7	0
474	Possibilities of peripheral magnetic neuromodulation in the treatment of lower urinary tract symptoms in men. Urology Herald, 2021, 9, 51-59.	0.1	2
475	Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR. Advances in Therapy, 2022, 39, 959-970.	1.3	6
476	Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial. International Journal of Clinical Practice, 2022, 2022, 1-9.	0.8	4
477	Botox for Erectile Dysfunction. Journal of Sexual Medicine, 2022, 19, 1061-1063.	0.3	1
478	The Association between Anticholinergic Medications for Overactive Bladder and Pneumonia. Annals of the American Thoracic Society, 2022, , .	1.5	0
479	Pelvic Floor Muscle Training in the Management of Female Pelvic Floor Disorders. Current Bladder Dysfunction Reports, 2022, 17, 115-124.	0.2	1
482	Does response to percutaneous tibial nerve stimulation predict similar outcome to sacral nerve stimulation?. Neurourology and Urodynamics, 2022, 41, 1172-1176.	0.8	3
483	Canadian Urological Association best practice report: Diagnosis and management of nocturia. Canadian Urological Association Journal, 2022, 16, .	0.3	4

#	ARTICLE	IF	CITATIONS
484	Postprocedural Pain Associated With 5 Versus 20 Intradetrusor Injections of onabotulinumtoxinA for Treatment of Overactive Bladder: A Multicenter Randomized Clinical Trial. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2022, Publish Ahead of Print, .	0.6	1
485	Combination and Novel Pharmacologic Agents for OAB. <i>Current Urology Reports</i> , 2022, , 1.	1.0	0
486	Selectivity and Maximum Response of Vibegron and Mirabegron for β_3 -Adrenergic Receptors. <i>Current Therapeutic Research</i> , 2022, 96, 100674.	0.5	18
487	Treatment of idiopathic overactive bladder with botulinum toxin: real-life results and patients'™ expectations. <i>Porto Biomedical Journal</i> , 2022, 7, e164.	0.4	0
488	First North American experience of propiverine use in children with overactive bladder. <i>Canadian Urological Association Journal</i> , 2022, 16, .	0.3	2
489	Development of sustained-release drug-loaded intravesical inserts via semi-solid micro-extrusion 3D-printing for bladder targeting. <i>International Journal of Pharmaceutics</i> , 2022, 622, 121849.	2.6	10
490	Does metabolic syndrome influence the efficacy of mirabegron treatment in female patients with overactive bladder?. <i>International Urogynecology Journal</i> , 2023, 34, 853-859.	0.7	1
491	Impact of Mirabegron Administration on the Blood Pressure and Pulse Rate in Patients with Overactive Bladder. <i>Medicina (Lithuania)</i> , 2022, 58, 825.	0.8	1
492	Biofeedback-assisted pelvic floor muscle training and pelvic electrical stimulation in women with overactive bladder: A systematic review and meta-analysis of randomized controlled trials. <i>Neurourology and Urodynamics</i> , 2022, 41, 1258-1269.	0.8	5
493	Risk factors for the development of acute pyelonephritis in women with a positive urine culture. <i>Neurourology and Urodynamics</i> , 2022, 41, 1582-1589.	0.8	6
494	Comparative dissolution studies of 3D-printed inserts in a novel biopharmaceutical bladder model. <i>International Journal of Pharmaceutics</i> , 2022, 624, 121984.	2.6	0
495	Neural networks outperform expert humans in predicting patient impressions of symptomatic improvement following overactive bladder treatment. <i>International Urogynecology Journal</i> , 2023, 34, 1009-1016.	0.7	1
496	Factors predicting the treatment success of bladder training for urgency urinary incontinence. <i>Neurourology and Urodynamics</i> , 0, , .	0.8	2
497	Effects of external electrical stimulation added to pelvic floor muscle training in women with stress urinary incontinence: A randomized controlled study. <i>Neurourology and Urodynamics</i> , 0, , .	0.8	1
498	To Compare the Effects of two Pelvic Floor Muscle Treatments on Quality of Life and Sexual Function in Female Patients With Urinary Incontinence. <i>Sexual Medicine</i> , 2022, 10, 100561.	0.9	1
499	Urgency and urgency incontinence following stress urinary incontinence surgery: A review of evaluation and management. <i>Indian Journal of Urology</i> , 2022, 38, 268.	0.2	3
500	Detrusor Pressure Estimation from Single-Channel Urodynamics. , 2022, , .		1
501	Vibegron for the treatment of overactive bladder: a comprehensive update. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1479-1484.	0.9	5

#	ARTICLE	IF	CITATIONS
502	Implementation of sacral neuromodulation for urinary indications. A Danish prospective study during the initial 15 months of a new service in a tertiary referral hospital. <i>Scandinavian Journal of Urology</i> , 2022, 56, 404-411.	0.6	0
503	Comparing clinical bladder diaries and recalled patient reports for measuring lower urinary tract symptoms in the symptoms of Lower Urinary Tract Dysfunction Research Network (LURN). <i>Neurourology and Urodynamics</i> , 2022, 41, 1711-1721.	0.8	5
504	Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis. <i>Drugs in Context</i> , 0, 11, 1-12.	1.0	2
505	An Update on Female Urethral Stricture Disease. <i>Current Urology Reports</i> , 2022, 23, 303-308.	1.0	3
506	Polyuria in patients with lower urinary tract symptoms: Prevalence and etiology. <i>Neurourology and Urodynamics</i> , 0, , .	0.8	3
507	Therapy of Sleep Disorders in Parkinsonâ€™s Disease. , 2022, , 4013-4031.		0
508	Editorial Comment: Intra-cavernous injection of BOTOX Â® (50 and 100 Units) for treatment of vasculogenic erectile dysfunction: Randomized controlled trial. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2022, 48, 990-991.	0.7	0
509	Evidence-Informed, Interdisciplinary, Multidimensional Action Plan to Advance Overactive Bladder Research and Treatment Initiatives: Directives From State-of-the-Science Conference on Overactive Bladder and Cognitive Impairment. , 2023, 29, S20-S39.		6
510	Effects of knee prosthetic surgery on overactive bladder symptoms and incontinence in women. <i>International Urogynecology Journal</i> , 0, , .	0.7	1
511	CYP2D6 Substrate Dispensing Among Patients Dispensed Mirabegron: An Administrative Claims Analysis. <i>Drugs - Real World Outcomes</i> , 2023, 10, 119-129.	0.7	2
512	Artificially sweetened beverages and urinary incontinenceâ€™ a secondary analysis of the Women's Health Initiative Observational Study. <i>Menopause</i> , 0, Publish Ahead of Print, .	0.8	0
513	Financial Toxicity for Female Patients with Urinary Incontinence. <i>Current Urology Reports</i> , 0, , .	1.0	1
514	Pre- versus Post-Menopausal Onset of Overactive Bladder and the Response to Vaginal Estrogen Therapy: A Prospective Study. <i>Medicina (Lithuania)</i> , 2023, 59, 245.	0.8	0
515	Anticholinergic Use for OAB in the Older Woman: An Update. <i>Current Geriatrics Reports</i> , 0, , .	1.1	0
516	Costâ€™effectiveness of overactive bladder treatments from a US commercial andâ€™payer perspective. <i>Journal of Comparative Effectiveness Research</i> , 2023, 12, .	0.6	0
517	Pathophysiology of Female Micturition Disorders. , 2022, , 1-14.		0
518	Behavioral Modification and Conservative Management of Overactive Bladder and Underactive Bladder Disorders. , 2022, , 1-33.		0
519	Meta-analysis of acupuncture-moxibustion treatment of overactive bladder in adults in the past decade. <i>Journal of Acupuncture and Tuina Science</i> , 2023, 21, 82-90.	0.1	0

#	ARTICLE	IF	CITATIONS
520	The effect of vitamin D on urgent urinary incontinence in postmenopausal women. International Urogynecology Journal, 0, , .	0.7	2
521	Telemedicine in Overactive Bladder Syndrome. Current Bladder Dysfunction Reports, 0, , .	0.2	0
522	Outcomes and postoperative management of autologous fascial pubovaginal slings in females who have failed a midurethral sling. , 2023, 6, 100027.		0
523	Dorsal oral mucosa graft urethroplasty for female urethral stricture reconstruction: A narrative review. Frontiers in Surgery, 0, 10, .	0.6	0
524	Intradetrusor OnabotulinumtoxinA injections at the time of Holmium Laser Enucleation of the Prostate (HoLEP) for men with overactive bladder symptoms. Journal of Endourology, 0, , .	1.1	0
525	Treating Incontinence for Underlying Mental and Physical Health (TRIUMPH): a study protocol for a multicenter, double-blinded, randomized, 3-arm trial to evaluate the multisystem effects of pharmacologic treatment strategies for urgency-predominant urinary incontinence in ambulatory older women. Trials. 2023. 24., .	0.7	0
532	Overactive-Bladder-Syndrom bei Frauen. Springer Reference Medizin, 2023, , 1049-1052.	0.0	0
540	Behavioral Modification and Conservative Management of Overactive Bladder and Underactive Bladder Disorders. , 2023, , 221-253.		0
541	Pathophysiology of Female Micturition Disorders. , 2023, , 71-84.		0
543	Electrical Stimulation Techniques by Implantable Devices. , 2023, , 121-131.		0
545	Effects of health education on women with urinary incontinence: systematic review and meta-analysis. International Urogynecology Journal, 2024, 35, 273-289.	0.7	0